NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the 'Start Date”). In connection with the commencement of Mr. Gengos’s employment, on July 16, 2026, Mr. Gengos was granted an option to purchase 650,000 shares of the Company’s Class A common stock ('Common Stock”) with a per share exercise price of $4.78, the closing trading price of the Common Stock on the Nasdaq Global Market on July 16, 2026 (the 'Closing Price”). The stock option was granted pursuant to the Company’s 2025 Employment Inducement Award Plan (the 'Inducement Plan”) and was approved by the Company’s Board of Directors (the 'Board”). The stock option has a ten-year term and vests (subject to Mr. Gengos’s continued service to the Company through the applicable vesting dates) as follows: 8.33333% of the initial shares underlying the option shall vest on each of the first, second and third monthly anniversary of the Start Date; 1.6667% of the initial shares underlying the option shall vest on the fourth monthly anniversary of the Start Date and on each monthly anniversary thereafter until the one-year anniversary of the Start Date; 3.33333% of the initial shares underlying the option shall vest on each monthly anniversary following the one-year anniversary of the Start Date until the second anniversary of the Start Date; and 0.833333% of the of the initial shares underlying the option shall vest on each monthly anniversary following the second anniversary of the Start Date until the fourth anniversary of the Start Date, such that the stock option shall be fully vested and exercisable on the fourth anniversary of the Start Date. The stock option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules (the 'Nasdaq Rules”) as an inducement material to Mr. Gengos entering into employment with the Company.